Wegovy is the weight-management version of semaglutide. The same molecule as Ozempic, with an approved dose ladder that climbs to 2.4 mg weekly, higher than the diabetes indication. The clinical evidence is well-established: the STEP trials showed an average weight loss of around 15 percent over 68 weeks, with meaningful improvements in cardiovascular risk markers.
Steady has Wegovy's titration schedule built in. The default ladder, 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg, four weeks at each step, is the path most women follow, but the app supports pausing the climb at any dose if the rate of weight loss is too fast or side effects are still acclimatising. The titration is a decision, not a treadmill.
Around the dose, the rest of the data layer: 120-gram protein targeting to protect lean mass, fourteen-symptom logging on a severity slider, cycle-aware coaching for the women whose cycles still move, and a research hub that explains the real-world questions, month-four plateaus, hair shedding, 'Ozempic face,' the metabolism after stopping. Every claim cites a primary source.
Built around how this medication actually works.
Wegovy's exact titration
0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg. Pause supported. Climb when you and your prescriber are ready.
Muscle-first nutrition
Protein target set to preserve lean mass through the steep early weight loss.
Plateaus, explained
Research hub plus your own data, the moving average, the four-week trend, the pattern that breaks them.
Cycle-aware logging
Symptom severity plotted by phase. Luteal-week nausea looks different from follicular-week nausea.
What the studies actually say.
Evidence-based summaries of the papers that informed every part of this page. Each article cites its sources.
Why 120 grams of protein matters when you can barely eat breakfast
A third of the weight lost on a GLP-1 can be muscle. Here's what the research says about protecting lean mass when appetite disappears.
Muscle on a GLP-1: the 2-hour-a-week rule that changes everything
Protein alone slows muscle loss. Protein plus two short resistance sessions a week preserves it. The evidence, and a practical starting plan.
The month-four plateau on a GLP-1: why it happens, and what to do about it
The first eight weeks fly. Then the scale stops. This is not the drug failing, it is your body doing what bodies do. Here's the maths, and the three levers that move it again.
Ozempic face: what it is, what helps, what doesn't
Loose skin and a hollow look after fast weight loss has a name now. It isn't the drug, it's the speed. Here's what the evidence says about slowing it down without slowing your…
Hair shedding on Ozempic: why it happens at month three, and what actually helps
Telogen effluvium is the medical name. Rapid weight loss is the trigger. Protein, iron, and patience are most of the answer.
GLP-1s and your heart: the protection that starts before the weight comes off
Ozempic and Mounjaro do more than shrink the scale. They lower the risk of heart attack and stroke, and the latest data shows the protection begins early, before most of the…
The thyroid black-box warning, explained for women on a GLP-1
Every GLP-1 label carries the same warning about thyroid tumours. The animal data is real. The human signal so far is small. Here is what to actually do with that information.
What happens when you stop a GLP-1, and the maintenance plan most prescribers forget to give you
STEP 1 Extension was honest about it: stopping the drug brings most of the weight back within a year, on average. Here is why, who keeps the weight off, and the maintenance plan…